American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Nov 2004
Randomized Controlled Trial Comparative Study Clinical TrialAdrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate.
Mometasone furoate (MF) and fluticasone propionate (FP) are high potency inhaled corticosteroids. The systemic bioavailability of MF is claimed to be negligible, leading to a minimal potential for systemic adverse effects. We assessed the overnight urinary cortisol/creatinine as the primary outcome of adrenal suppression in 21 patients with persistent asthma (mean FEV1 = 91%). ⋯ For secondary outcomes of 8:00 A. M. plasma cortisol, serum osteocalcin, and early morning urinary cortisol/creatinine, there was significant suppression with MF and FP at the highest dose. Our data refute the assertion that MF has negligible systemic bioavailability and a lower potential for systemic adverse effects compared with FP.